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The assessment of cardiac risk in noncardiac surgery has been developed and refined for approximately 20 years. Recent studies have evaluated patients undergoing vascular surgery, for they constitute a selected population with a high risk of significant coronary artery disease. 1 Physiologic factors that predispose to myocardial ischemia include elevations in heart rate and blood pressure, as well as an increase in postoperative platelet reactivity. 2 β-Adrenergic receptor antagonists (β-blockers) are known to be effective in reducing heart rate and blood pressure. Several observational studies have shown a decreased incidence of myocardial ischemia and perioperative myocardial infarction
Data collected
Data were collected to allow assessment of the patients' postoperative cardiac risk. These factors included a history of known coronary artery disease, previous MI, angina pectoris, congestive heart failure (CHF), hypertension, and history of diabetes mellitus requiring therapy (Table I) . These risk factors were considered present only if they were documented in the patient's medical record.
Data regarding the administration of β-blockers, calciumchannel antagonists, and angiotensin-converting enzyme inhibitors also were collected. Medications on admission were defined as those taken as an outpatient on a long-term basis. Inpatient preoperative medications included those given from admission up to the time of surgery. Postoperative medications included all doses from the time the patient left the operating room until discharge or the 30th postoperative day.
Exposure
Perioperative withdrawal of β-blocker therapy was defined as a patient treated with β-blockers before surgery (at least up to within 1 day of the procedure) who did not receive the medication postoperatively. Possible contraindications to postoperative β-blocker readministration were also measured in all patients (those with and those without β-blocker discontinuation). Those possible contraindications (postoperative CHF, need for postoperative vasopressor administration, or bradyarrhythmia requiring therapy or medication withdrawal) were considered present if they occurred in the postoperative period before β-blocker readministration in patients who had β-blockers restarted. The contraindications to β-blocker administration were considered present at any time postoperAmerican Heart Journal Volume 141, Number 1 Shammash et al 149 compared with coronary artery bypass surgery patients. The aim of our study was to examine the impact of postoperative β-blocker withdrawal on mortality and cardiovascular events in vascular surgical patients.
Methods

Study population
A list of consecutive vascular surgical patients at a university hospital (University of Pennsylvania Medical Center) between January 1, 1995, and September 30, 1995, was obtained by a computerized search of the medical records system with use of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure codes, which included endarterectomy (38.1), resection of vessel with anastomosis or replacement (38.3, 38.4), other shunt or vascular bypass (39.2), revision of vascular procedure (39.4), and other repair of vessels (39.5). Surgeries were excluded if they were associated with a lower level of cardiac risk (posttraumatic, postcomplication, and hemodialysis access procedures) or with a higher level of cardiac risk (any surgery requiring cardiopulmonary bypass).
A similar list of consecutive vascular surgical patients was derived at a second university hospital (New York Presbyterian Hospital-Weill Cornell Center) for patients undergoing the above procedures, excluding carotid endarterectomy, in 1997 and 1998. Carotid endarterectomy was excluded in the second retrospective cohort of patients because these patients were found to have a lower incidence of cardiac events in the first cohort and because experts consider carotid endarterectomy to be surgery associated with intermediate cardiac risk, versus aortic, other major vascular, and peripheral vascular surgery, which are considered high-risk procedures. 14 (2) 2 (1) 1 (12) COPD, Chronic obstructive pulmonary disease; CEA, carotid endarterectomy; AAA, abdominal aortic aneurysm repair. Table I . Risk factors and β-blocker discontinuation atively in patients who had their β-blockers permanently discontinued.
Outcomes
The primary outcome was in-hospital mortality. This outcome was chosen because it is not susceptible to surveillance bias. To assess cardiac-specific outcomes, secondary outcomes included cardiac death and fatal or nonfatal MI. Cardiac death was defined as mortality confirmed at autopsy to be the result of MI or death occurring after MI and resulting from an arrhythmia or cardiac failure. MI was defined as an elevation of creatine kinase MB isoenzyme fraction greater than 2.5% or 3.0% of total creatine kinase (the respective laboratory cutoff values for the two hospitals) plus postoperative chest pain, new Q waves, ST segment, or T-wave changes on electrocardiogram (ECG) compared with the preoperative ECG, or acute MI confirmed by autopsy.
Statistical analysis
Odds ratios (ORs), exact 95% confidence intervals (CIs), and exact P values were calculated to assess the relationship between β-blocker withdrawal and the outcomes. The study was designed to examine predictors of β-blocker use and was not specifically designed to test the significance of a predetermined OR. However, the power of the study is reflected in the CIs. Exact stratified analyses were performed to assess the possible confounding effect of each cardiac risk factor and of contraindications to restarting β-blockers postoperatively. Exact logistic regression was then used to adjust simultaneously for confounders. The small number of deaths prohibited adjustment for all possible confounders for the primary outcome; therefore adjustment was made only for those variables that might have created a false association between β-blocker discontinuation and death (ie, this analysis did not adjust for factors that increased the OR for β-blocker discontinuation). For the analysis of postoperative MI, subjects first receiving β-blockers postoperatively only after symptoms of myocardial ischemia, ECG changes, or elevated creatine kinase MB fractions developed were considered to have had their β-blockers discontinued before the infarction. All analyses were performed with use of SPSS version 9 (SPSS, Chicago, Ill), StatXact version 3 (Cytel Software, Cambridge, Mass), and LogXact version 4 (Cytel). The study was approved by the Institutional Review Board at both hospitals.
Results
Prevalence of β-blocker administration and discontinuation
Sixty-one of 222 vascular surgical patients (27%) in the first cohort were receiving β-blockers before surgery. Fifty-five patients had documented use of β-blockers as outpatients and the other 6 received β-blockers in the inpatient preoperative period. β-Blockers were discontinued in 6 (10%) of 61 patients who received β-blockers preoperatively.
All 79 patients in the second cohort received preoperative β-blockers (by design). β-Blockers were discontinued in 2 (2.5%) patients.
Patient demographics and surgery type
Of the 140 patients receiving β-blockers preoperatively, 30 underwent carotid endarterectomy (21%), 34 abdominal aortic aneursym repair (24%), 73 peripheral arterial surgery (52%), and 3 other major vascular surgeries (2%). The prevalence of risk factors for postoperative cardiac events or possible contraindications to β-blocker readministration are listed in Table I . Patients in this vascular surgery cohort had an expected high prevalence of hypertension, prior MI, angina, advanced age, and diabetes mellitus. Patients who had β-blockers discontinued did not have statistically significant differences with respect to age, history of MI, angina, diabetes mellitus, CHF, and bradyarrhythmia. Patients who had β-blockers discontinued had a higher prevalence of relative contraindications to restarting β-blockers postoperatively. No patients with β-blocker discontinuation had a history of asthma, chronic obstructive pulmonary disease, or ventricular arrhythmia requiring therapy.
Postoperative β-blocker discontinuation and outcomes
The overall mortality incidence was 3.6%, with 10 deaths in 275 patients. Among those patients receiving β-blockers preoperatively, there were 6 deaths (4.3%). There were 5 deaths in patients who underwent periph- Table II . Effect of β-blocker discontinuation on outcomes eral arterial revascularization, and 1 death in a patient undergoing thoracic abdominal aortic aneurysm repair. Two deaths were cardiac related; both occurred in patients who underwent peripheral arterial revascularization and both were confirmed at autopsy by evidence of acute MI. Eleven patients who received β-blockers preoperatively had postoperative nonfatal MIs (7.9%).
One patient receiving β-blockers preoperatively in the first cohort had evidence of MI occurring preoperatively (an elevated creatine kinase with elevated CK-MB relative index recorded during surgery) and was therefore excluded from the analysis of postoperative MI. Postoperative β-blocker withdrawal was associated with an increased risk of events (Table II) . Four of 8 patients (50%) whose β-blocker therapy was discontinued died compared with 2 of 132 patients (1.5%) who were continued on β-blocker therapy (unadjusted OR 65, 95% CI 6.3-815, Table II ). This association persisted after controlling, in stratified analyses, for each risk factor: history of angina (OR 46, 95% CI 5.0-669), MI (OR 50, 95% CI 5.8-676), diabetes mellitus (OR 100, 95% CI 7.8-5914), CHF (OR 82, 95% CI 6.6-4778), age (OR 47, 95% CI 5.3-626), and surgery type (OR not calculable, P < .001).
Of note, 3 of the 8 patients whose β-blockers were discontinued had hemodynamic events that might have prohibited restarting β-blockade (defined as postoperative CHF, need for postoperative vasopressor administration, or bradyarrhythmia requiring therapy or medication withdrawal). Although adjustment for these potential contraindications diminished the OR, the strong association persisted (adjusted OR 35, 95% CI 3.2-557). After the patients with potential contraindications to restarting β-blockers were excluded, there was still an increased risk of death or MI (OR 18.3, 95% CI 1.8-233; P = .006). For death alone, the results were not statistically significant, but the CIs were very wide (OR 19.7, 95% CI 0.25-451; P = .09). Furthermore, adjusting simultaneously for all variables that reduced the OR and therefore might have created a false association between β-blocker withdrawal and mortality (age, angina, MI, and contraindications to restarting β-blockers), the multivariable OR remained significant (adjusted exact OR 17.0, 95% CI 1.81-224; P = .01). Further adjustment for the other factors would likely have increased the OR but was not possible as discussed in Methods.
The impact of aspirin, warfarin, and class Ia antiarrhythmic medication discontinuation on β-blocker discontinuation and death was assessed in the subset of patients with known status of drug use (University of Pennsylvania Medical Center) because these medications may have an impact on perioperative cardiac outcomes. After adjustment for aspirin or warfarin discontinuation, the results were unchanged. Adjustment for class Ia antiarrhythmic drug discontinuation led to a reduction in the OR for stopping β-blockers and death (unadjusted OR 54 reduced to 41), but the results remained statistically significant (P < .001).
β-Blocker discontinuation was also associated with an
Figure 1
Risk of death and MI among subjects with medications continued versus subjects with medications discontinued. For analyses of MI, one patient with an intraoperative infarction was excluded from the cohort. In one subject restarted on an angiotensin-converting enzyme inhibitor postoperatively the exact start time could not be determined. BB, β-Blocker; CCB, calcium channel antagonist; ACEI, angiotensin-converting enzyme inhibitor.
increased risk for cardiovascular outcomes (Table II) . There were no cardiac deaths in patients who had β-blockers restarted and 2 deaths (28.6%) in those with β-blocker discontinuation (P = .005). The risk of MI also was elevated in patients withdrawn from β-blockers (Table II) . This increased OR for MI, which was statistically significant in its unadjusted form, remained significant with adjustment for age, surgery type, contraindications to restarting β-blockers, angina, heart failure, diabetes, and history of MI (adjusted exact OR 19.4, 95% CI 1.19-1414; P = .03). β-Blocker discontinuation was also associated with an increased risk for any death or MI (Table II) , which persisted after adjustment for the same variables discussed above (adjusted exact OR 19.3, 95% CI 1.96-328; P = .007).
Discontinuation of other medications and outcomes
To determine whether bias produced the β-blocker results, the effects of withdrawal of calcium channel antagonists and angiotensin-converting enzyme inhibitors were examined. The discontinuation of calcium channel antagonists and angiotensin-converting enzyme inhibitors were both associated with a modest to moderate increase in risk of mortality and MI, but none of these associations was statistically significant ( Figure  1 ). The ORs (95% CI) for calcium channel antagonists were 1.6 (0.03-21) for death and 5.3 (0.72-30.8) for MI; for angiotensin-converting enzyme inhibitors, they were 13.3 (0.96-708) for death and 6.6 (0.42-97) for MI. There was only one cardiac death among patients who were given angiotensin-converting enzyme inhibitors or calcium channel antagonists preoperatively. Although there was an increased risk of mortality associated with the discontinuation of these medications, the associations were not statistically significant and were of smaller magnitude, albeit with wide CIs.
Discussion
The results of our study suggest an increased risk of mortality and cardiovascular events associated with β-blocker discontinuation in vascular surgery patients, a group of patients with a relatively high prevalence of coronary artery disease and risk factors for perioperative morbidity and mortality. In evaluating the relationship between inpatient postoperative mortality and β-blocker discontinuation, we have tried to account for potential confounders that may have been associated with β-blocker use or withdrawal and with an increased mortality risk. Furthermore, the discontinuation of calcium channel antagonists and angiotensin-converting enzyme inhibitors, medications that often have similar indications for discontinuation but do not have the withdrawal effect seen with β-blockers, were not associated with the same risk as β-blocker withdrawal, although the number of patients are too small to draw any firm conclusions. Nevertheless, our finding of increased mortality and cardiovascular events associated only with β-blocker withdrawal supports the argument that the particular pharmacologic characteristics of β-blockers, and of their discontinuation, contribute to the increased mortality seen with β-blocker withdrawal.
Previous studies have documented deleterious effects from β-blocker withdrawal in surgical patients. These effects may be mediated through a hyperadrenergic response to stress, which may occur as the result of an increased number of β-receptors that develops with long-term β-adrenergic receptor blockade. 10 However, heterogeneity among β-blockers, in properties such as lipophilicity, likely results in different mechanisms of β-blocker withdrawal. In a cohort study comparing abrupt withdrawal of propranolol within 24 hours before coronary artery bypass grafting to patients whose dose was tapered over an average of 3 days and then discontinued 24 hours before surgery, abrupt withdrawal resulted in a 4-fold higher rate of perioperative MI (7% vs 32%), and all six patients who died as a result of perioperative MI had been abruptly withdrawn from propranolol. 13 A separate trial with propranolol in aortocoronary bypass surgery showed that patients assigned to be withdrawn from propranolol preoperatively had a higher incidence of perioperative and intraoperative myocardial ischemia and arrhythmias than those patients assigned to continue on propranolol, although they did not have an elevated rate of postoperative MI or mortality. 15 However, this latter small study is difficult to interpret because 25% of patients assigned to have their β-blockers withdrawn did not.
The benefits of perioperative β-blockade in reducing perioperative myocardial ischemia in vascular surgery have been demonstrated. 3, 4, 7 Data from a case-control study involving 2088 vascular surgical patients also found an association between β-blocker use and a decreased incidence of perioperative MI. 5 A randomized controlled trial by Mangano et al 8 in noncardiac surgery patients demonstrated a long-term reduction in postdischarge mortality and cardiac events over a 2-year follow-up period in patients with coronary artery disease or at risk for coronary disease who had received perioperative atenolol versus placebo. The occurrence of perioperative ischemia in this study was associated with long-term postoperative cardiac events. A recent randomized controlled study of high-risk patients undergoing major vascular surgery showed a significant reduction in cardiac death and nonfatal MI in those patients receiving bisoprolol perioperatively. 9 These data suggest that effectively limiting perioperative myocardial ischemia through perioperative β-blocker administration can have significant longterm benefits on reducing cardiac event rates and that discontinuing β-blockers might be deleterious.
The above studies provide data to further assess the impact of perioperative β-blocker withdrawal in noncardiac surgery. Eight of the 101 patients receiving placebo perioperatively in the atenolol study 6 had received β-blockers before randomization and were therefore at risk for β-blocker withdrawal. While the impact of β-blocker withdrawal on postoperative mortality was not discussed in that publication, Mangano 16 noted, in a separate correspondence, a 12% 2-year postoperative mortality rate (1/8) among patients receiving β-blockers preoperatively but randomized to the placebo group versus 6% (1/18) for patients on β-blockers preoperatively who were randomized to β-blockers postoperatively. That is, in a clinical situation similar to that of our study patients whose preoperative β-blockers were discontinued postoperatively had a mortality rate twice as high as that for patients whose β-blockers were continued. These data, although of small sample size, are suggestive, but certainly not proof, of an increased risk associated with β-blocker withdrawal. Further study of the impact of β-blocker withdrawal on mortality is clearly warranted.
There are several limitations to our study. First, because of the small number of patients withdrawn from β-blockers, it is possible that our finding is a spurious one. Second, the study was not randomized and therefore subject to confounding by indication (ie, that medical conditions associated with increased perioperative mortality influenced the decision to prescribe or withhold β-blockers postoperatively). However, adjustment for contraindications to β-blocker readministration diminished, but did not negate, the finding of increased risk of all-cause mortality in those patients whose β-blockers were discontinued. Although the results were not statistically significant after those with potential contraindications were excluded, the numbers were very small and the CIs very wide. Also, the results remained significant for the combined outcome of death or MI in this subgroup. Furthermore, the results were unchanged after adjusting simultaneously for other risk factors and for possible contraindications to β-blocker readministration. However, these contraindications were determined retrospectively by chart review, and therefore their accuracy and completeness are somewhat limited. A randomized trial of β-blocker discontinuation would overcome these limitations, but we are concerned that such a study may be unethical, given the evidence supporting the adverse effects of β-blocker discontinuation. [10] [11] [12] 16 Another possible explanation for our results is that cause and effect were reversed, that is, death prevented β-blocker readministration. However, if this were so, then the same striking association between mortality and discontinuation seen with β-blockers should have been observed with calcium channel antagonists and angiotensin-converting enzyme inhibitors. Although there was an increased risk of mortality associated with the discontinuation of these medications, the associations were not statistically significant and were of smaller magnitude.
In conclusion, β-blocker discontinuation in vascular surgical patients may be associated with an increased risk of postoperative morbidity and mortality. Further study confirming our results would provide additional support for this conclusion. Meanwhile, in the absence of serious potential contraindications to β-blocker use, and given current evidence, efforts must be made to ensure that patients treated with β-blockers before vascular surgery have their β-blockers continued as soon as possible in the postoperative period.
